These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 9633877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR, Martin MB.
    N Engl J Med; 1998 Dec 03; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract] [Full Text] [Related]

  • 6. The effectiveness of deferiprone in thalassemia.
    Dogherty P, Einarson T, Koren G, Sher G.
    Blood; 1997 Jul 15; 90(2):894. PubMed ID: 9226195
    [No Abstract] [Full Text] [Related]

  • 7. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar 15; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 8. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Mar 15; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 9. Iron mobilization using chelation and phlebotomy.
    Flaten TP, Aaseth J, Andersen O, Kontoghiorghes GJ.
    J Trace Elem Med Biol; 2012 Jun 15; 26(2-3):127-30. PubMed ID: 22565013
    [Abstract] [Full Text] [Related]

  • 10. Deferiprone for thalassaemia.
    Kontoghiorghes GJ, Agarwal MB, Grady RW, Kolnagou A, Marx JJ.
    Lancet; 2000 Jul 29; 356(9227):428-9. PubMed ID: 10972396
    [No Abstract] [Full Text] [Related]

  • 11. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT, Tsai CH, Wu KH.
    Hemoglobin; 2008 Jul 29; 32(1-2):49-62. PubMed ID: 18274983
    [Abstract] [Full Text] [Related]

  • 12. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul 29; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 13. [Iron chelation in 1998].
    de Montalembert M.
    Transfus Clin Biol; 1998 Oct 29; 5(5):353-6. PubMed ID: 9836396
    [Abstract] [Full Text] [Related]

  • 14. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
    Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ.
    J Cardiovasc Magn Reson; 2011 Jul 06; 13(1):34. PubMed ID: 21733147
    [Abstract] [Full Text] [Related]

  • 15. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
    Piga A, Gaglioti C, Fogliacco E, Tricta F.
    Haematologica; 2003 May 06; 88(5):489-96. PubMed ID: 12745268
    [Abstract] [Full Text] [Related]

  • 16. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003 May 06; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 May 06; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 18. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ.
    Lancet; 2003 Aug 09; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract] [Full Text] [Related]

  • 19. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 20. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ.
    Hemoglobin; 2006 Jul 18; 30(2):329-47. PubMed ID: 16798657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.